Join our daily newsletter At The Bell to receive exclusive market insights
- Uscom’s (UCM) BP+ product has received approval for sale in China, from the Chinese National Medical Products Administration (NMPA)
- The BP+ is a patent-protected high-fidelity central blood pressure monitor, which measures blood pressure parameters from three sites within the arteries
- With BP+’s entry into the Chinese market, the approval will allow Uscom to gain a new stream of sales revenue
- The NMPA certificate will be issued to the company within the next ten working days
- Uscom is up 6.45 per cent and trading at 16 cents per share
Uscom’s (UCM) BP+ product has received approval for sale in China, from the Chinese National Medical Products Administration (NMPA).
The NMPA is a regulatory body, which regulates medical device approval in China. The administration has given the approval after 26 months of testing and validating the company’s technology.
The BP+ is a patent-protected high-fidelity central blood pressure monitor device. It measures and provides information about 34 parameters of blood pressure from three different sites in the arteries, which was once only accessible via invasive cardiac catheters.
Combined with Uscom’s BP+ Reporter, the product provides some of the most advanced technology for blood pressure monitoring of hypertension and vascular health. In addition to having applications in home care, the BP+ is also applicable in traditional hospital departments like the ICU, Emergency, Cardiology, CCU, Obstetrics and ED’s.
Uscom already has one product, the USCOM 1A cardiovascular monitor, which has NMPA approval for sale in China. In 2020, the USCOM 1A has generated approximately $3.75 million in annual revenue.
With BP+’s entry into the Chinese market, the NMPA approval will allow Uscom to gain a second stream of sales revenue.
Uscom’s Executive Chairman, Associate Professor Rob Phillips, called the NMPA approval of the BP+ a significant endorsement for the company’s technology, as well as an incremental financial opportunity.
“While the 1A is a hospital sale, the BP+ is an advanced consumer product with a far larger market, and combined with the BP+ Reporter, sets new standards for monitoring hypertension and vascular health worldwide,” he said.
“The BP+ solution is anticipated to generate significant new revenue as the devices are fed into our growing network of Chinese distributors,” he added.
The certificate from the NMPA should be issued to Uscom within the next ten working days.
Uscom is up 6.45 per cent, trading at 16 cents per share at 3:09 pm AEST.
